RAD51D and breast carcinoma: GPVs of RAD51C and RAD51D are known to impart susceptibility to breast cancer at absolute risks of 15–40% (NCCN Guidelines® Version1.2022 at www.nccn.org, accessed on 19 November 2021), while both of them are shown to moderately increase susceptibility to ovarian cancer, such as a six-fold higher risks for carriers of RAD51D variant [46].